Karin Elebro et al. demonstrated that patients with breast cancer with discordant HR status (ER+AR− or ER−AR+) had a worse prognosis compared to concordant HR status (ER+AR+ or ER−AR−), with ER−AR+ tumors being associated with the worst prognosis [7]. This evidence concerns the gene AR and breast carcinoma.